Pfizer’s talazoparib prolonged the time until disease progression or death in breast cancer patients with inherited BRCA mutations, compared to standard chemotherapy, in a Phase 3 trial of the treatment. The company now plans to present the data to global health authorities with the aim of getting the treatment approved for this group of breast cancer patients, who currently have limited treatment options. “Patients with germline BRCA-positive breast cancer are typically diagnosed at a younger age than those with non-hereditary breast cancer, and there are no therapies specifically approved for them outside of current standard of care therapies,” Jennifer Litton, MD, lead investigator of the trial, said in a press release. Researchers presented the data at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5-9. The Phase 3 EMBRACA trial (NCT01945775) is the largest study to date examining a PARP inhibitor — a drug class targeting DNA repair processes — in patients with advanced or metastatic breast cancer and inherited BRCA mutations. The median progression-free survival in patients treated with talazoparib in the trial was 8.6 months, which was significantly longer than the 5.6 months in patients treated with standard chemotherapy, according to their physician's choice.